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Background: Previous studies have demonstrated a profound lack of habituation in 129P3 mice compared to the
habituating, but initially more anxious, BALB/c mice. The present study investigated whether this non-adaptive
phenotype of 129P3 mice is primarily based on anxiety-related characteristics.
Methods: To test this hypothesis and extend our knowledge on the behavioural profile of 129P3 mice, the effects
of the anxiolyticdiazepam (1, 3 and 5 mg/kg) and the putative anxiolytic metabotropic glutamate receptor 5
(mGlu5R) antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP, 3, 10 and 30 mg/kg) treatment on within-trial
(intrasession) habituation, object recognition (diazepam: 1 mg/kg; MPEP 10 mg/kg) and on the central-nervous
expression of the immediate early gene c-Fos (diazepam: 1 mg/kg; MPEP 10 mg/kg) were investigated.
Results: Behavioural findings validated the initially high, but habituating phenotype of BALB/c mice, while 129P3
mice were characterized by impaired intrasession habituation. Diazepam had an anxiolytic effect in BALB/c mice,
while in higher doses caused behavioural inactivity in 129P3 mice. MPEP revealed almost no anxiolytic effects on
behaviour in both strains, but reduced stress-induced corticosterone responses only in 129P3 mice. These results
were complemented by reduced expression of c-Fos after MPEP treatment in brain areas related to emotional
processes, and increased c-Fos expression in higher integrating brain areas such as the prelimbic cortex compared
to vehicle-treated 129P3 mice.
Conclusions: These results suggest that the strain differences observed in (non)adaptive anxiety behaviour are at
least in part mediated by differences in gamma-aminobutyric acid- A and mGluR5 mediated transmission.
Keywords: Anxiety, Behavior, Benzodiazepines, C-Fos, Cortisosterone, mGluR5 antagonistBackground
Adaptive anxiety in mice may be characterised by
changes in behavioural responses over time, for example
habituation to a novel environment. In contrast, non-
adaptive anxiety might be mirrored by a lack of such a
habituation, a phenomenon which may severely interfere
with the normal interaction of the animal with its phys-
ical and social environment [1-3].* Correspondence: ambersalomons@gmail.com
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reproduction in any medium, provided the orRecently, we found that 129P3/J mice are character-
ized by a profound lack of habituation to the modified
hole board test as shown by highly increased avoidance
behaviour over time while BALB/c mice, which have
been reported to be highly anxious [4,5], show rapid ha-
bituation to the same test environment [2]. In addition,
in 129P3/J mice c-Fos expression was found to be lower
after the habituation procedure in distinct brain areas
(e.g. prelimbic cortex and lateral septum) in comparison
to BALB/c mice [2]. In a subsequent study we further
demonstrated that exposure to chronic mild stress prior
to repeated behavioural testing intensified the lack of ha-
bituation also in other behavioural parameters such as
locomotion [6]. Other studies have found specificral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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locomotor activity and more anxiety-related behaviour
compared to for example C57BL/6 mice [7,8]. From
these and our results we concluded that 129P3/J mice
may represent an interesting animal model for non-
adaptive anxiety.
However, it remains unclear whether the profound
lack of habituation in 129P3/J mice is primarily based on
anxiety-related characteristics. For example, avoidance
behaviour can be confounded by other motivational sys-
tems, such as exploration [7,9,10] or cognitive processes
[3,11,12]. We hypothesise that if the habituation profile
in 129P3 mice was primarily based on anxiety-related
characteristics, anxiolytic treatment should improve the
habituation capacity in these mice.
To test this hypothesis, two anxiolytic compounds
were used in the present study: the benzodiazepine
Diazepam as a standard anxiolytic, and the metabotro-
pic glutamate receptor 5 antagonist (mGlu5R) MPEP
(2-methyl-6-(phenylethynyl)pyridine). Diazepam has shown
anxiolytic efficiency over decades [13,14]. However, this
compound is known to induce side effects at the cognitive
level i.e. amnesia as well as in activity sedation [13-15].
Therefore, the putative anxiolytic MPEP was included in
the present study. A number of studies have shown anxio-
lytic properties of MPEP [16-18]. For example, MPEP sig-
nificantly reduced fear potentiated startle [18] and
increased the number of open arm entries in the elevated
plus maze, similar as treatment with diazepam [19] Further-
more, treatment with MPEP attenuated stress-induced
hyperthermia and decreased the number of buried marbles
in a marble burying test, whereas no effect of MPEP treat-
ment was observed on spontaneous locomotor activity [18].
Since our previous studies evaluated between trial or
intersession habituation, we were now interested in
extending our knowledge about the behavioural profile
in 129P3/J mice by investigating within-trial intrasession
habituation as well. It has been suggested that
intersession habituation reflects memory or retention of
the previous exposures, while intrasession habituation
might indicate adaptive capacity [12].
In the present study, the two mouse strains BALB/c
and 129P3/J, were tested after acute treatment with
either diazepam or MPEP for 30 minutes in the open
field (intra-session habituation), and an object recogni-
tion test (cognitive performance). In addition to behav-
ioural parameters, levels of plasma corticosterone
(CORT) were determined before and after behavioural
testing. Finally, the expression of c-Fos, a marker for
neural activity [20,21], was investigated after behavioural
testing in brain areas involved in emotional and
cognitive processing. Based on the hypothesis that the
non-adaptive phenotype of 129P3 mice is primarily
anxiety-related, we expected anxiolytic treatment tofacilitate habituation and decrease post-testing cortico-
sterone levels. In addition we expected enhanced c-Fos
expression in brain areas involved in the integration of
emotional and cognitive processes.
Methods
Animals and housing
Naive male BALB/cJ (BALB/c, stock nr. 000651) and
129P3/J (129P3, stock nr. 000690) were obtained from
the Jackson Laboratory (Bar Harbour, Maine, USA) and
housed individually in Eurostandard Type II cages (size:
26.7 × 20.7 × 14 cm, Tecniplast, Buguggiate, Italy) pro-
vided with bedding material (LignocelW, J. Rettenmaier
& Söhne GmbH, Germany), a tissue (KLEENEXW Facial
Tissue, Kimberly-Clark Professional BV, Ede, The
Netherlands) and a shelter for cage enrichment. Mouse
chow (CRM, Expanded, Special Diets Services Witham,
England) and tap water were available ad libitum. For all
experiments, the mice were acclimated to the experimental
room for 17 days at the animal facilities of The Netherlands
Vaccine Institute (Bilthoven, The Netherlands) under a
reversed dark/light cycle (lights on between 18.00 h and
6.00 h). A radio played constantly as background noise
(radio music interspersed with talk-shows, +/−60 dB). Dur-
ing this period the animals were handled three times a
week by the person who also performed the behavioural
tests. All behavioural testing took place between 9.00 and
13.00 h in the animal’s housing room and equipment
(including the behavioural test set-ups) was installed before
the animals arrived. Relative humidity was kept at a con-
stant level of approximately 50%, room temperature was
sustained at 22 °C±2 and ventilation rate was 15–20 air
changes per hour.
The experimental protocols were approved by the Ani-
mal Experiments Committee of the Academic Biomedical
Centre Utrecht, The Netherlands. Furthermore, all animal
experiments followed the ‘Principles of Laboratory Animal
Care’ and refer to the Guidelines for the Care and Use of
Mammals in Neuroscience and Behavioural Research (Na-
tional Research Council 2003).
Drugs
Diazepam (BUFA, The Netherlands) and 2-methyl-
6-(phenylethynyl)-pyridine (MPEP, Hoffmann-La Roche,
Basel, Switzerland) were prepared in 0.1 % Tween 80
and saline in a volume of 10 ml/kg and injected i.p. in
the experimental room 30 minutes prior to behavioural
testing. Vehicle treatment consisted of 0.1 % Tween 80
and saline and was injected i.p. 30 minutes prior to be-
havioural testing. Anxiolytic effects after diazepam
treatment in BALB/c mice have been found in a dose
range of 1–5 mg/kg [22]. For MPEP treatment, anxiolytic
effects have been found in a dose range of 3–30 mg/kg
[17,18]. There is no knowledge about diazepam and MPEP
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was included in the open field test.
Experiment 1: the open field (OF)
A total of 56 mice per strain were used and randomly
assigned to 3 different dose groups per compound and
one vehicle group (n = 8 per treatment group). Animals
were tested with either diazepam (1, 3 or 5 mg/kg),
MPEP (3, 10 or 30 mg/kg) or vehicle. While we used one
vehicle group only in order to decrease the number of
animals needed, the diazepam or MPEP treated mice
were considered as parallel experiments and were thus
analyzed per compound. Although, all treated mice were
tested conjointly in a given test session in order to prevent
variability of baseline behaviours among experiments. For
all animals, diazepam MPEP or vehicle was i.p. injected
30 minutes before behavioural testing. Thirty minutes
after behavioural testing a blood sample was taken and
120 minutes after testing the animals were euthanized by
decapitation and brains were removed.
Apparatus
The OF apparatus consisted of a circular grey PVC arena,
80 cm in diameter and 33 cm high grey PVC walls (Add-
itional file 1: Figure A1a). The arena was divided by red
concentric circles in an outer zone, inner zone and centre
area. Extra lines radiating out from the centre were placed
on the floor as indicator for locomotion. One extra light
bulb (red light) was fastened above the arena making the
light intensity in the OF about 5–10 lux. Each animal
was individually placed in the OF for 30 minutes, always
starting from the same position at the edge of the OF. Be-
haviour was directly monitored and scored by a trained
observer blind to treatment group using the program Ob-
server 5.0 (Noldus Technology, The Netherlands). After
each trial the OF was carefully cleaned with tap water and
a towel. Behaviours scored in the OF included avoidance
behaviour of the centre area, risk assessment, locomotor
and exploratory behaviour and arousal. A description of
all behaviours measured can be found in Table 1.
Blood samples
Basal blood samples (basal) were collected 4 days before
the start of the OF using tail vein incision for cortico-
sterone (CORT) determination. Thirty minutes after be-
havioural testing a second blood sample was taken
(non-basal). For blood sampling, mice were transported
individually in their home cage to an adjacent laboratory
(in order not to disturb circadian rhythm of the mice,
the hallway and rooms were under red light conditions).
By using tail vein incision a small blood sample was col-
lected (±50 μl) and stored in prechilled Microvette tubes
(CB300, Sarstedt, Numbrecht, Germany) containing lith-
ium heparin. Blood samples were centrifuged (10 min at12000 rpm, 4 °C) and stored at −20 °C until measurement.
CORT levels were measured by radioimmunoassay (RIA)
according to the protocol of the supplier with an Immu-
Chem™ Double Antibody Corticosterone kit for rats and
mice (MPI Biochemicals, Amsterdam, The Netherlands).
c-Fos
Brains from treatment groups: vehicle, 1 mg/kg diaze-
pam and 10 mg/kg MPEP were removed for c-Fos
immunohistochemistry. After removal, brains were fro-
zen in liquid (−80 °C) 2-methylbutane which was cooled
with dry ice and stored at −80 °C. Coronal sections were
cut (20 μm) and mounted on Menzel SuperFrost Plus
slides (Menzel GmbH & Co, Braunschweig, Germany)
and stored at −20 °C. The sections were processed for
c-Fos immunohistochemistry as described previously [2],
dilution with a polyclonal primary antibody (1:1000,
SC-52 Santa Cruz Biotechnology, Santa Cruz, USA), and
a donkey-anti-rabbit IgG Biotin SP conjugated secondary
antibody (1:400, Jackson ImmunoResearch Laboratories,
Inc USA). Cells containing a nuclear brown-black reac-
tion product were considered as c-Fos positive cells and
counted in several brain areas which are known to be
involved in anxiety [23-25]: medial prefrontal cortex
(prelimbic, PrL), lateral septum (dorsal, LSD; intermedi-
ary, LSI; ventral, LSV), bed nucleus of the stria terminalis
(medial anterior, BSTMA; lateral posterior, BSTLP; med-
ial ventral, BSTMV), hippocampus (granular layer den-
tate gyrus, DG), hypothalamus (paraventricular nucleus,
PVN; dorsal medial hypothalamus, DMH), amygdala
(basolateral nucleus, BLA; central nucleus cAmy) and
the periaqueductal gray (dorsolateral, dlPAG; dorsome-
dial, dmPAG; lateral, lPAG; ventrolateral, vlPAG). The
anatomical localization was aided by use of adjacent
Nissl stained sections and the illustrations in a stereo-
taxic atlas [26]. For each region at least two overt land-
marks were used. For quantitative analysis of c-Fos
positive cells, the program Leica Qwin (image processing
and analysis software, Cambridge, United Kingdom) was
used. Left and right hemispheres were analyzed for
stained neurons per mm2 and calculated for one section
separately and averaged for each animal.
Experiment 2: the object recognition test (ORT)
Results from the open field led to the conclusion that
1 mg/kg diazepam and 10 mg/kg MPEP could be used
as the minimal effective dose range, without causing side
effects in both strains. We used these doses to investi-
gate object memory. A total of 27 mice per strain was
used for the ORT (n = 9 per treatment group). On day 1,
the familiar object was placed in the home cage. On day
2, the animals were i.p. injected with diazepam
(1 mg/kg), MPEP (10 mg/kg) or vehicle 30 minutes be-
fore behavioural testing. Thirty minutes after the ORT, a
Table 1 Overview of behavioural parameters measured in the open field and the object recognition test
Behavioural parameter Abbreviation Behavioural dimension
Experiment 1: Open Field Latency until the first centre entry Latency centre Avoidance behaviour
Total time spent in centre Centre duration
Total number of centre entries Centre entries
Total number of stretched attends Stretched attends Risk assessment
Latency until first stretched attend Latency stretched attend
Total number of line crossings Line crossings Locomotion
Latency until first line crossing Latency line cross
Total time spent immobile Immobility duration
Latency until the first immobility event Latency immobility
Total number of rearings Rearings General exploration
Latency until first rearing Latency rear
Total time spent grooming Grooming duration Arousal/de-arousal
Latency until the first grooming event Latency grooming
Total number of fecal boli defecations
Experiment 2: Object recognition test Discrimination index* DI Object memory
Latency until first exploration novel object Latency novel object
Latency until first exploration familiar object Latency familiar object
Total time spent exploring novel object Time novel object
Total time spent exploring familiar object Time familiar object
Total number of stretched attends Stretched attends Risk assessment
Total number of line crossings Line crossings Locomotion
Total time spent immobile Immobility duration
Latency until the first immobility event Latency immobility
Total number of rearings Rearings General exploration
Total time spent grooming Grooming duration Arousal/de-arousal
Latency until the first grooming event Latency grooming
* The DI was calculated as followed: (total exploration time novel object – total exploration time familiar object) / total time spent exploring novel + familiar
object.
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the animals were euthanized by decapitation.
Apparatus
The test apparatus was a Eurostandard Type II L cage
(size: 36.5 x 21 x 14 cm; Tecniplast, Buguggiate, Italy)
without any bedding and equally divided in 6 squares by
black lines on the floor (Additional file 1: Figure A1b).
Light conditions were the same as in the experimental
room, red light with an illumination intensity of approxi-
mately 5 lux. Two different objects were used that differed
in colour, material and shape (screw nut and die). Both
objects were considered too heavy to be displaced by the
animals. All animals were allowed to familiarize with one
of the two objects for 24 h in their home cage (rando-
mized for each strain and treatment i.e. half the animals of
each testing group received a nut, the other half received a
die) one day before the ORT. Twenty-four hours later, the
animals were tested in a one-trial ORT, withouthabituation to the test arena. This was done to study the
effect of anxiolytic treatment on object memory per se.
Both objects (for the familiar object a duplicate was used)
were always placed in the same corner of the apparatus,
each was positioned at the same distance from the wall.
For testing, the animals were individually placed in the ap-
paratus always in the same corner opposite of the objects
and scored by a trained observer blind to treatment group
for 10 minutes. After each trial the ORT was carefully
cleaned with tap water and a towel. Behaviours scored in
the ORT included object memory, risk assessment, loco-
motor and exploratory behaviour and arousal. A descrip-
tion of all behaviours measured can be found in Table 1.
Blood samples
Basal blood samples (basal) were collected 4 days before
the start of the ORT using tail vein incision for cortico-
sterone (CORT) determination. Thirty minutes after the
ORT a second blood sample was taken (non-basal). The
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the OF (section 2.3.2).
Statistics
All statistical analyses were carried out according to
Field [27] using the software program SPSSW for Win-
dows (version 16.0.1; SPSS Inc., IL, USA). Two-sided,
exact i.e. for the non-parametric tests probabilities were
estimated throughout. Continuous numerical data
(CORT, c-Fos, latency and relative duration of behav-
ioural parameters) were summarized as means with
standard error of the mean (SEM), whereas discrete data
on the ordinal scale (total number of behavioural para-
meters) were represented as medians with the interquar-
tile range (IQR). The Kolmogorov-Smirnov one-sample
test was used to check Gaussanity of the continuous nu-
merical data. Several parameters that were not normally
distributed were transformed to a Gaussian distribution
by using a mathematical function or by rank transform-
ation [28]. Discrete numerical data (total numbers of the
behavioural parameters of the open field) were fist rank-
transformed. Behavioural numerical data from the open
field and CORT values were tested for significant differ-
ences by multivariate repeated measures ANOVA [29].
Tests of significance were derived using the Wilk’s
lambda criterion (for the open field, time interval was
taken as within-subject factor and strain and dose as
between-subject factors). For CORT values the basal/
non-basal CORT was taken as within-subject factor and
strain and dose as between-subject factors. For latency
and defecation data of the OF, ORT data and c-Fos
results, a two-way ANOVA was used with strain and
treatment (or dose for the open field) as main between-
subject factors. If ANOVA detected significant effects,
group means were further compared. Between-subject
post hoc comparisons were done with either unpaired
Student’s t tests for normally distributed data, or for non-
normally distributed data and for discrete data, the same
comparisons were performed using a Wilcoxon-
Mann–Whitney test. For the ORT this was done to
investigate whether the discrimination index differed sig-
nificantly from zero i.e. no discrimination between novel
and familiar object. To take the greater probability of a
Type I error due to multiple hypotheses into account, we
calculated for each behavioural category separate so-called
Dunn-Šidák corrections: ANOVA’s: α=1 – [1–0.05]1/q;
q=number of parameters per behavioural category; post
hoc Student’s t tests, the Wilcoxon-Mann–Whitney tests,
and Wilcoxon matched-pairs signed ranks tests: α = 1 –
[1 – 0.05]1/q; q = number of parameters per behavioural
dimension multiplied by the number of times a group is
used for a meaningful comparison. The corrected
thresholds used for the ANOVA’s and post hoc compari-





In general, vehicle-treated BALB/c mice initially showed
more avoidance behaviour of the unprotected centre of
the OF compared to vehicle-treated 129P3 mice. While
BALB/c mice showed a decrease in avoidance behaviour
across the experimental period, 129P3 mice did not,
confirming a lack of habituation in these mice. Whereas
diazepam treatment decreased initial anxiety in BALB/c
mice, higher doses caused clear immobility in 129P3
mice. In contrast, MPEP exerted only minor behavioural
effects in both strains.
Diazepam Avoidance behaviour: treatment with diaze-
pam did not affect the latency until the first centre entry.
In contrast, a time interval effect (F5;48) = 2.559, P< 0.05)
was found for the time spent in the centre. Furthermore,
a time interval (F5;52) = 3.817, P< 0.05) and time x strain
interaction (F5;52) = 5.226, P< 0.0170) effect for the num-
ber of centre entries (Figure 1). Neither strain nor dose
effects were found, suggesting that the time interval ef-
fect of the ANOVA was independent of these factors.
Post hoc testing revealed no differences between trials in
the time spent in the centre. Vehicle-treated BALB/c
mice made more centre entries in time interval 6 when
compared to time interval 1 (P< 0.01), thereby showing
less avoidance behaviour across the experimental period.
No post hoc effects were found in 129P3 mice, suggest-
ing that neither vehicle-treated nor diazepam treated
mice showed a change in avoidance behaviour across the
experimental period.
Risk assessment: ANOVA revealed a time interval ef-
fect (F5;51) = 14.116, P< 0.05), dose effect (F3;55) = 8.476,
P< 0.05) and time interval x dose interaction
(F15;141.2) = 2.264, P< 0.05) effect for the number of
stretched attends (Figure 2). Post hoc testing showed that
1, 3 and 5 mg/kg diazepam-treated BALB/c mice showed
a significant decrease in the number of stretched attends
across the time intervals (P< 0.01). Vehicle-treated ani-
mals of both strains showed a decrease in the number of
stretched attend for the last time interval only (P< 0.01).
These results suggest that diazepam especially decreased
initial risk assessment behaviour, which was independent
of strain. No effects were observed for the latency until
the first stretched attend.
Locomotor activity: ANOVA revealed a significant
strain (F1;55) = 46.839, P< 0.05), and time interval x
strain interaction (F5;51) = 7.245, P< 0.05) effect for the
number of line crossings. Post hoc testing showed an in-
crease in the number of line crossings across the time
Figure 1 The number of centre entries during open field testing. Animals were pre-treated with vehicle, diazepam or MPEP. Data are
displayed as the mean number (± SEM) of centre entries during each time interval of 5 min each. Significant time effects were found after both
treatments.
Salomons et al. Behavioral and Brain Functions 2012, 8:30 Page 6 of 13
http://www.behavioralandbrainfunctions.com/content/8/1/30intervals in vehicle-treated BALB/c mice (P< 0.01). No
differences in the number of line crossings across the
time intervals were observed in 129P3 mice. Whereas
ANOVA detected no significant dose effects, BALB/c
mice showed more line crossings than 129P3 mice after
pre-treatment with 3 and 5 mg/kg (P< 0.01). No effects
were found for the latency until the first line crossing.
For immobility duration, a significant strain
(F1;55) = 17.084, P< 0.05), dose (F3;55) = 8.076, P< 0.05)
and strain x dose interaction (F3;55) = 5.268, P< 0.05) ef-
fect were found. Post hoc testing revealed that 129P3
mice after treatment with 3 and 5 mg/kg diazepam spent
more time immobile when compared to vehicle-treated
mice (P< 0.01). No significant post hoc effects were
observed in BALB/c mice, suggesting that only 129P3
mice were affected in their immobility duration after
diazepam treatment. For the latency until the first im-
mobility event, ANOVA revealed a significant dose(F3;55) = 4.294, P< 0.05) effect. Post hoc testing showed
that pre-treatment with 3 and 5 mg/kg diazepam
decreased the latency until the first immobility event
(P< 0.01).
Exploration and arousal behaviour effects can be found
in the supplementary results. Also a general overview of
all behavioural results from the OF after diazepam treat-
ment can be found in Additional file 1: Table A3.
MPEP Avoidance behaviour: ANOVA revealed strain
(F1;55) = 6.626, P< 0.05) differences in latency until the
first centre entry. Post hoc testing revealed that BALB/c
mice showed a higher latency to enter the centre area
when compared to 129P3 mice (P< 0.01), suggesting
more initial avoidance behaviour than 129P3 mice. For
centre duration a time interval effect (F5;51) = 5.332,
P< 0.05) was observed. Post hoc testing showed
increased time spent in the centre across the time
Figure 2 The number of stretched attends during open field testing. Animals were pre-treated with vehicle, diazepam or MPEP. Data are
displayed as the mean number (± SEM) of centre entries during each time interval of 5 min each. Significant time and dose effects were found
after diazepam treatment, but only time effects after MPEP treatments.
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treatment. While ANOVA detected a time interval effect
in the number of centre entries (F5;51) = 6.334, P< 0.05,
Figure 1), post hoc testing did not reveal any significant
differences between the time intervals.
Risk assessment: ANOVA detected a significant time
interval effect (F5;51) = 21.231, P< 0.05), and strain x
time interval interaction (F5;51) = 4.270, P< 0.05) effect
for the number of stretched attends (Figure 2). Post hoc
testing showed that the number of stretched attends
decreased across the time intervals in both strains, al-
though BALB/c showed more initial risk assessment
behaviour when compared to 129P3 mice. Also, BALB/c
mice showed more stretched attends after 10 mg/kg
MPEP when compared to 129P3 mice (P< 0.05). No
effects were observed for the latency until the first
stretched attend.Locomotor activity: after MPEP treatment, ANOVA
revealed a significant time interval x strain interaction
effect (F5;51) = 6.651, P< 0.05). Post hoc testing showed a
significant increase in the number of line crossings
across the time intervals in BALB/c mice. No significant
differences were observed in the number of line cross-
ings between BALB/c and 129P3 mice. For latency until
the first line crossing, a significant strain effect
(F1;55) = 10.418, P< 0.05) was observed, although post
hoc testing did not reveal a significant difference be-
tween the strains. No significant effects were observed
for immobility duration. For latency until the first im-
mobility event, ANOVA detected a significant dose ef-
fect (F3;55) = 5.314, P< 0.05). Post hoc testing showed
that pre-treatment with 10 mg/kg significantly increased
the latency until the first immobility event (P< 0.01),
which was independent of strain.
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found in the supplementary results. Also a general
overview of all behavioural results from the OF after
MPEP treatment can be found in Additional file 1
Table A4.Corticosterone
Diazepam: basal/non-basal (F1;53) = 33.331, P< 0.05),
strain (F1;53) = 5.285 , P< 0.05), dose (F3;53) = 4.885 ,
P< 0.05), and strain x dose interaction (F3;53) = 3.467,
P< 0.05) effects were found (Figure 3). Post hoc
testing showed that behavioural testing increased
CORT levels, which was indicated by a significantly
higher value for both BALB/c and 129P3 mice in
vehicle-treated animals after testing (P< 0.01). In
BALB/c mice, non-basal CORT levels decreased after
5 mg/kg diazepam as compared to non-basal levels
in vehicle-treated BALB/c mice. Furthermore, 1 mg/kg
diazepam decreased non-basal CORT values as com-
pared to non-basal values of vehicle-treated 129P3
mice (P< 0.0052). The reverse was observed after
pre-treatment with 3 and 5 mg/kg diazepam, which
significantly increased CORT values compared to
basal levels in 129P3 mice as shown by post hoc testing
(P< 0.01, Figure 3).
MPEP: basal/non-basal (F1;47) = 29.661, P< 0.05) and
strain effects (F1;47) = 5.125, P< 0.05) were found
(Figure 4). Post hoc testing revealed that CORT levels
were generally higher after behavioural testing when
compared to basal levels (P< 0.01). Additionally, post
hoc testing revealed that 129P3 mice showed generally
higher CORT levels as compared to BALB/c mice,
although basal and non-basal values did not significantly
differ in 129P3 mice, whereas BALB/c mice showed
significantly higher non-basal CORT values (P< 0.01).
No dose effects were found. See also Additional file 1:
Table A5.Figure 3 Mean (± SEM) CORT levels after diazepam treatment. CORT d
testing in the OF for BALB/c mice (left) and 129P3 mice (right). * = significac-Fos immunohistochemistry
Brains from animals treated with vehicle, 1 mg/kg diaze-
pam and 10 mg/kg MPEP were processed for c-Fos
immunohistochemistry.
In vehicle-treated mice, strain differences were
observed in the PrL (F(1;79) = 18.377, P< 0.05, Figure 5a),
LSD (F(1;79) = 15.999, P< 0.01) and DG (F(1;79) = 32.194,
P< 0.05). BALB/c mice showed more c-Fos expression
in these areas (P< 0.01) when compared to 129P3 mice,
which is in accordance with our previous findings. After
1 mg/kg diazepam treatment, higher c-Fos expression
was found in the PrL, DG and BLA in BALB/c mice
compared to 129P3 mice (P< 0.01). Compared to
vehicle-treated mice, diazepam-treated BALB/c showed
less c-Fos positive cells in the PrL, PVN, LSD, and LSV
(P< 0.01), while diazepam-treated 129P3 mice showed
lower c-Fos expression in the PVN, BLA and DMH
compared to vehicle-treated 129P3 mice. After MPEP
treatment a different c-Fos expression pattern was
observed. BALB/c mice showed more c-Fos positive cells
in the PVN compared to 129P3 mice (P< 0.01,
Figure 5b). Lower c-Fos expression was found after
MPEP-treatment compared to vehicle treatment in
BALB/c mice in the PrL, PVN, DMH, LSD, LSV, lPAG
and vlPAG (P< 0.01). MPEP treatment in 129P3 mice
induced lower c-Fos expression in the PVN, DMH, LSV,
BLA and higher c-Fos expression in the PrL, DG,
BSTMV and BSTMA compared to vehicle-treated 129P3
mice (P< 0.05). See also Additional file 1 Table A6.
Object recognition test
Behaviour
Strain differences were observed for the discrimination
index (F(1;44) =6.718, P< 0.05) and post hoc testing
revealed a higher discrimination index in BALB/c mice
compared to 129P3 mice after vehicle treatment
(Figure 6). Additionally, within-subject post hoc compari-
sons were made to investigate whether the discriminationata are displayed before (basal) and after (non-basal) behavioural
ntly different after post hoc comparisons.
Figure 4 Mean (± SEM) CORT levels after MPEP treatment. CORT data are displayed before (basal) and after (non-basal) behavioural testing in
the OF for BALB/c mice (left) and 129P3 mice (right). * = significantly different after post hoc comparison.
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treated BALB/c mice showed a positive discrimination
index (t = 4.057, P = 0.01), indicating that these mice
spend more time investigating the novel object compared
to the familiar object. In contrast, vehicle-treated 129P3
mice showed no significant difference from zero, thereby
demonstrating no difference between novel and familiar
object exploration. Furthermore, post hoc testing showed
that pre-treatment with diazepam, both strains showed
no positive discrimination index, whereas MPEP did not
affect discrimination between the objects in BALB/c
mice. In contrast, pre-treatment with MPEP slightly
increased the discrimination index in 129P3 mice, al-
though this failed to reach significance (P< 0.054). No
significant strain or treatment effects were found for the
latency to explore the novel or the familiar object.
Results from other behavioural parameters measured in














































Figure 5 Mean number of c-Fos positive cells (± SEM) after pre-treatm
treatment in the OF. Data are displayed for the PrL (left) and the PVN (rigCorticosterone
Significant basal/non-basal (F1;33) = 35.522, P< 0.05) and
strain (F1;33) = 23.344, P< 0.05) effects were found. Post
hoc testing revealed that 129P3 mice had higher CORT
levels than BALB/c mice. Furthermore, CORT levels
were increased after behavioural ORT testing as com-
pared to basal levels (P< 0.01). No significant treatment
effects were found; see also Additional file 1: Table A8.
Discussion
General findings open field
Results from the present study demonstrated a signifi-
cant intrasession habituation in BALB/c mice. In support
of previous results [2] it seems that BALB/c mice indeed
are characterized by an initially high but adaptive anxiety
profile, which was shown by decreased anxiety-related
behaviour over time. In contrast vehicle-treated 129P3
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Figure 6 Discrimination index (± SEM) after vehicle, diazepam
or MPEP treatment in the ORT. ANOVA revealed significant strain
differences in DI (* = significantly different after post hoc
comparisons); One-sample t-statistics revealed significant differences
from zero ($ = significantly different from zero).
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and locomotor behaviour throughout the experimental
period. Similar results were found by Tang et al. [8], who
showed that BALB/c mice spent increased time in the
centre of an open field during a 30 minute trial. The
same study also demonstrated impaired habituation after
30 minutes open field testing in 129P3 mice. Valid evalu-
ation of anxiety-related behaviour is suggested to be
dependent on a comparable activity level [30].Both
strains showed a comparable activity level at the onset of
the testing trial, but only BALB/c mice increased their
activity level over time. In contrast, such an increase was
not observed in 129P3 mice. Apparently, the non-
adaptive habituation phenotype in 129P3 mice deter-
mines their behaviour between as well as within sessions,
a phenomenon found in different test systems [2,6,8],
suggesting that this lack of habituation is a general char-
acteristic in the 129P3 inbred strain, which is independ-
ent of their activity levels.Open field: effects of diazepam treatment
The general strain differences identified are further
extended by the results of the pharmacological treat-
ment. Whereas only minor treatment effects were
observed on avoidance behaviour in the open field, the
results nevertheless suggest a different response between
the strains. Diazepam treatment decreased risk assess-
ment behaviour and post-testing CORT levels only in
BALB/c mice. Other studies have found anxiolytic
effects of diazepam in BALB/c mice [22,31,32]. In con-
trast, diazepam treatment in 129P3 mice induced
marked sedation. This difference in sensitivity towardsdiazepam treatment is likely to be due to strain charac-
teristics in benzodiazepine receptor densities or sensitiv-
ity. BALB/c mice have been shown to exhibit a five-fold
decrease in the density of benzodiazepine binding sites
as compared to C57BL/6 mice [33]. While there are no
reports on diazepam treatment in 129P3 mice, some
pharmacological studies however have reported sedative
effects of benzodiazepines in other 129 substrains. For
example, Rodgers [30] found sedation in 129 S2 mice
after chlordiazepoxide treatment and suggested that
129 S2 mice have an abnormal benzodiazepine/GABA-A
receptor function. The same might be true for 129P3
mice as well. It is of note that the higher doses (3 and
5 mg/kg) of diazepam not only produced sedation in
129P3 animals but increased their post-testing CORT
levels as well when compared to both vehicle-treated
129P3 mice and diazepam-treated BALB/c mice. This ef-
fect suggests either an activating effect on the HPA axis
[34], or an emotionally aversive effect of the treatment-
induced sedation in 129P3 animals [35]. Furthermore,
acute diazepam treatment is known to cause hyperther-
mia in members of another substrain of the 129 family,
129 Sv mice [36]. Thus, diazepam might interfere with
temperature regulation in 129P3 mice as well, which
may be another explanation for the side effects observed.
It should be mentioned though, that the diazepam doses
used in the Open Field might have been too high. While
a similar dose range has been used in BALB/c mice
[4,22], it could very well be that sedation might be
observed when animals are tested in their home cage.
The apparent sedation in BALB/c mice could have been
masked by increased vigilance in the behavioural test
set-up.
Open Field: effects of MPEP treatment
Notably, a different picture emerged after treatment with
MPEP in the two strains. Avoidance, risk assessment
and locomotor activity were unaffected by pre-treatment
with MPEP in both strains. Lack of effect on locomotor
behaviour corresponds to existing literature on MPEP
[18,37]. Although anxiolytic effects of MPEP have been
found in several animal models of anxiety [16-19], MPEP
hardly had any effect on avoidance behaviour in both
strains. Close inspection of MPEP treatment in 129P3
mice did reveal a decrease in avoidance behaviour, al-
though it failed to reach significance. The anxiolytic
effects of both compounds did show a difference be-
tween the strains; diazepam decreased risk assessment
behaviour in both strains, whereas MPEP increased risk
assessment behaviour in BALB/c mice, while it
decreased in 129P3 mice. The relationship between risk
assessment behaviour and avoidance behaviour was
found to be independent as shown by factor analyses
[38,39] Furthermore, it has been shown that risk
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[40]. The existence of such a subtle anxiolytic effect of
MPEP in 129P3 mice was further underlined by
decreased post-testing CORT levels at all MPEP doses in
129P3 mice, an effect that could not be found in BALB/
c mice.
c-Fos
The strain-specific findings were extended by the results
on c-Fos expression in different brain areas in the open
field. Brain areas involved in the integration of emotional
and cognitive processes, such as the PrL, DG, BST and
LS [41-44] were found to be more active after MPEP
treatment in 129P3 mice, whereas the Amy and PVN,
brain areas primarily involved in emotional processes
[45,46], showed lower c-Fos activity as compared to
vehicle-treated 129P3 mice. In contrast, diazepam treat-
ment in BALB/c mice especially resulted in decreased
c-Fos expression in brain areas related to emotional pro-
cessing, while no effects were found on higher cortical
anxiety-related brain areas. Notably, strain differences in
the PrL, DG and LSD in vehicle treated animals could
not be found in MPEP treated animals.
An explanation for the strain-specific diazepam or
MPEP treatment effects, respectively, is that diazepam
and MPEP exert their anxiolytic effects via different
mechanisms [47]. Given the fact that the two strains are
further characterized by specific anxiety-phenotypes, dis-
tinct regulatory systems, underlying the specific pheno-
types, may be suggested: diazepam is known to act
inhibitory via the GABA-A system. In diazepam-treated
BALB/c mice, we found c-Fos expression in the PVN,
known to regulate HPA-axis activity, and the BLA,
known to process anxiety-responses, to be reduced;
these effects were not seen in 129P3 mice. In contrast,
MPEP produced a different c-Fos expression profile in
other brain areas in both strains, while 129P3 mice
appeared to be more sensitive for MPEP.
mGlu5 receptors are highly expressed in several limbic
structures such as the hippocampus, amygdala and
septum [48,49] and activation of these receptors leads to
excitatory effects in the brain, such as an increase of glu-
tamatergic transmission [50-52]. A controlled glutama-
tergic transmission is known to be critical for higher
order mental processes, whereas excessive glutamatergic
transmission can lead to impairment of normal neural
processes and even cell death [53,54]. Notably, it has
been suggested that anxiety disorders may arise through
excessive excitatory neurotransmission in response to
stress [55]. For MPEP it has been shown that glutamate
release is effectively reduced after acute treatment [56].
Interestingly, MPEP increased c-Fos expression in the
PrL, and BST in 129P3 mice, when compared to vehicle
treated animals, suggesting that higher order processesregulated by the prefrontal cortex are affected in
addition to primarily emotional processes. From the
present results as well as from our previous studies in
129P3 mice we conclude that the prelimbic cortex seems
to play an important role in the phenotype of 129P3
mice. This is further supported by the notion that 129P3
mice display impaired fear extinction [57], a process
which relies on a reciprocal connection between the pre-
limbic cortex and the amygdala [58]. The prelimbic cor-
tex has been shown to act as the cognitive control
system in emotional processing [41,59]. Given the fact
that MPEP treatment increased c-Fos expression in the
prelimbic cortex in 129P3 mice as compared to BALB/c
mice and vehicle-treated 129P3 mice, it may be hypothe-
sised that it is primarily the cognitive control over their
emotionality which determines the behavioural profile of
the 129P3 strain. However, at present we cannot exclude
the possibility that the increased c-Fos expression is
related to other neural processes and further studies are
necessary to investigate which neurons become activated
during the habituation procedure. In any case, it seems
likely that reduced c-Fos expression in the prelimbic
cortex in 129P3 mice is related to their non-adaptive
anxiety phenotype.
Object recognition
It has repeatedly been suggested that pathological, or
non-adaptive anxiety may primarily be a specific, but
not general, cognitive dysfunction [3,60]. To control for
general cognitive functioning, we investigated the effects
of the (putative) anxiolytic pre-treatment in a one trial
object recognition test in both strains as well. As found
earlier [2], BALB/c mice discriminated between the
novel and familiar object. The fact that after diazepam
treatment no positive discrimination index was found in
this strain is likely to be explained by diazepam induced
amnesic effects, which have been extensively reported
[61,62]. In contrast to our earlier findings, vehicle-
treated 129P3 mice showed no positive discrimination
index, a discrepancy which may be explained by differ-
ences in experimental design: in our previous study, but
not in the present one, animals were habituated to the
test environment, which might be of impact on explor-
ation behaviour especially in 129P3 mice. In this study
we intentionally chose not to habituate the animals to
the test environment, in order to investigate the effects
of anxiolytic treatment on object memory per se. Al-
though not statistically significant, the discrimination
index indicates a trend towards a dose dependent im-
provement in object memory after MPEP treatment in
129P3 mice. This however would be in contrast to other
findings that either no effects of MPEP are found on re-
trieval of object memory [37,63] or even impaired object
recognition [64].
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Treatment with either diazepam or MPEP did not facili-
tate habituation in the open field and had only minor
effects on anxiety-related behaviour in 129P3 mice. In
contrast, the effect of MPEP on stress-induced CORT
responses and c-Fos expression does support our hypoth-
esis of a primarily anxiety-related phenotype in 129P3
mice. While these results seem contradictory at the first
glance, several studies have found discrepancies between
effects on physiological and behavioural readout-
parameters of anxiety, with physiological measures some-
times being more sensitive [65]. It would thus be of inter-
est to investigate anxiety-related parameters in 129P3
mice, which are not based on approach-avoidance behav-
iour [66]. In any case, based on the present findings it
can be suggested that the observed strain differences in
(non)adaptive anxiety behaviour are at least partly
mediated by differences in GABAergic and mGluR5
mediated transmission. Further investigation of the func-
tional role of these systems will help for a better under-
standing of the underlying neurobiological mechanisms
of non-adaptive anxiety.Additional file
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